Skip to content

Perspective Therapeutics CATX Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$111.13M-7.8%-$103.12M+2.5%-$105.8M-11.4%-$94.95M-11.5%-$85.17M-7.4%
$3.65M+12.1%$3.25M+10.2%$2.95M+3.7%$2.84M+6.0%$2.68M+16.3%
$9.42M+5.1%$8.97M+2.9%$8.72M+2.4%$8.51M+24.7%$6.83M+26.8%
-$92.37M-12.0%-$82.48M+2.3%-$84.43M-30.3%-$64.78M-20.6%-$53.72M-194%
$14.95M+17.3%$12.75M-42.8%$22.29M-55.4%$50.01M0.0%$50M-8.1%
-$62.76M-252%$41.23M+133%-$125.91M+25.8%-$169.64M+4.3%-$177.2M+19.1%
$54K+3.8%$52K+2.0%$51K-5.6%$54K+10.2%$49K+2.1%
$164.71M+1,496%$10.32M-3.2%$10.66M-3.7%$11.08M-91.7%$133.03M-54.0%
-$107.32M-12.7%-$95.23M+10.8%-$106.72M+7.0%-$114.78M-10.7%-$103.72M-42.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Perspective Therapeutics generate?
Perspective Therapeutics (CATX) generated -$92.4M in operating cash flow over the trailing twelve months.
What is Perspective Therapeutics's free cash flow?
After $15.0M of capital expenditures, Perspective Therapeutics's free cash flow was -$107.3M over the trailing twelve months, down 3.5% year over year.
Where does Perspective Therapeutics's cash flow data come from?
Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.